JP2024023228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023228A5 JP2024023228A5 JP2023188623A JP2023188623A JP2024023228A5 JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5 JP 2023188623 A JP2023188623 A JP 2023188623A JP 2023188623 A JP2023188623 A JP 2023188623A JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- molecule
- hla
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506674P | 2017-05-16 | 2017-05-16 | |
| US62/506,674 | 2017-05-16 | ||
| JP2019563546A JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| PCT/US2018/032996 WO2018213467A1 (en) | 2017-05-16 | 2018-05-16 | Manabodies and methods of using |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Division JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023228A JP2024023228A (ja) | 2024-02-21 |
| JP2024023228A5 true JP2024023228A5 (https=) | 2024-08-01 |
| JP7701079B2 JP7701079B2 (ja) | 2025-07-01 |
Family
ID=64274676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| JP2023188623A Active JP7701079B2 (ja) | 2017-05-16 | 2023-11-02 | Ｍａｎａボディおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11807662B2 (https=) |
| EP (2) | EP3635000A4 (https=) |
| JP (2) | JP7381345B2 (https=) |
| CN (1) | CN111406068A (https=) |
| AU (2) | AU2018269370B2 (https=) |
| CA (1) | CA3063905A1 (https=) |
| WO (1) | WO2018213467A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| WO2020172332A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| TW202128765A (zh) * | 2019-11-21 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雙特異性抗體 |
| EP4077370A4 (en) * | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| WO2021255189A1 (en) * | 2020-06-17 | 2021-12-23 | Tiziana Life Sciences, Plc | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies |
| CN116867519A (zh) * | 2020-12-01 | 2023-10-10 | 约翰斯霍普金斯大学 | 治疗t细胞癌症的方法和材料 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| WO2025106598A1 (en) * | 2023-11-13 | 2025-05-22 | Clasp Therapeutics, Inc. | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP3738308B2 (ja) | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| CN102558352A (zh) | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| US20050042218A1 (en) | 2003-07-10 | 2005-02-24 | Vaccinex, Inc. | MHC class I - peptide-antibody conjugates with modified beta2-microglobulin |
| US7655751B2 (en) * | 2004-01-23 | 2010-02-02 | Green Peptide Co., Ltd. | Epidermal growth factor receptor-derived peptides |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| EP1863846B1 (en) | 2005-03-25 | 2009-07-22 | Ramot at Tel-Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| AR057807A1 (es) | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
| JP2009521474A (ja) | 2005-12-21 | 2009-06-04 | メディミューン，エルエルシー | ＥｐｈＡ２ＢｉＴＥ分子およびその使用 |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| DK2714733T3 (da) | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3126390B2 (en) | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| MX384919B (es) * | 2014-11-26 | 2025-03-14 | Us Health | Receptores de células t de kras anti-mutado. |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| CN115873129A (zh) | 2015-03-23 | 2023-03-31 | 约翰·霍普金斯大学 | 由体细胞突变基因编码的hla限制性表位 |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| KR20180023949A (ko) | 2015-06-09 | 2018-03-07 | 메모리얼 슬로안-케터링 캔서 센터 | 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| JP7185524B2 (ja) | 2015-09-15 | 2022-12-07 | アメリカ合衆国 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| CN116063544A (zh) | 2016-02-03 | 2023-05-05 | 安进研发（慕尼黑）股份有限公司 | Bcma和cd3双特异性t细胞接合抗体构建体 |
| JP7500195B2 (ja) * | 2016-08-23 | 2024-06-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
| WO2018071796A2 (en) | 2016-10-13 | 2018-04-19 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US20200325244A1 (en) * | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| CA3080274A1 (en) | 2017-09-29 | 2019-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| EP3720478A1 (en) | 2017-12-04 | 2020-10-14 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class i-restricted t cell receptors against mutated ras |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN111344015B (zh) | 2019-12-23 | 2022-09-30 | 深圳市人民医院 | 一种用于癌症治疗的光纳米疫苗及其制备方法和应用 |
-
2018
- 2018-05-16 US US16/614,005 patent/US11807662B2/en active Active
- 2018-05-16 AU AU2018269370A patent/AU2018269370B2/en active Active
- 2018-05-16 CA CA3063905A patent/CA3063905A1/en active Pending
- 2018-05-16 CN CN201880047554.3A patent/CN111406068A/zh active Pending
- 2018-05-16 JP JP2019563546A patent/JP7381345B2/ja active Active
- 2018-05-16 EP EP18802867.4A patent/EP3635000A4/en not_active Withdrawn
- 2018-05-16 WO PCT/US2018/032996 patent/WO2018213467A1/en not_active Ceased
- 2018-05-16 EP EP25190769.7A patent/EP4644427A3/en active Pending
-
2023
- 2023-09-25 US US18/473,695 patent/US20240294648A1/en active Pending
- 2023-11-02 JP JP2023188623A patent/JP7701079B2/ja active Active
-
2025
- 2025-05-21 AU AU2025203767A patent/AU2025203767A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023228A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| JP2021512635A5 (https=) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2023123502A5 (https=) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2019525771A5 (https=) | ||
| JP2025142045A5 (https=) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2021536265A5 (https=) | ||
| JP2018538277A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2020512973A5 (https=) | ||
| JP2019535262A5 (https=) | ||
| JPWO2019157533A5 (https=) | ||
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| CN115066274A (zh) | 三价结合分子 | |
| JPWO2022133169A5 (https=) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JPWO2021184673A5 (https=) | ||
| JPWO2020051493A5 (https=) | ||
| JPWO2019191120A5 (https=) | ||
| JPWO2021127184A5 (https=) | ||
| JPWO2020104676A5 (https=) | ||
| JPWO2020037066A5 (https=) |